Adverse Event in Clinical Research: Meaning, Types & Reporting

Executive Summary

The robust management of adverse events (AEs) is a foundational element in clinical research, extending beyond mere regulatory compliance to encompass a profound ethical and scientific responsibility. This report provides a comprehensive overview of adverse events within the clinical research landscape, delineating their precise definitions, various classifications, and the intricate reporting mechanisms. It underscores that effective pharmacovigilance necessitates a proactive approach to safety stewardship, where the stringent reporting timelines and continuous safety evaluations serve as critical mechanisms for anticipating and mitigating potential harm. This commitment ensures the safeguarding of participant well-being, the preservation of data integrity, and the responsible advancement of new medical interventions.

1. Introduction: The Cornerstone of Clinical Safety

Clinical trials are meticulously designed to evaluate both the efficacy and safety of novel medical interventions.¹ Within this critical process, adverse events represent any untoward medical occurrences that manifest in participants during the course of a study.² A thorough understanding of these events is fundamental to comprehensively characterize the risk-benefit profile of any new medicinal product.²

The ethical principles that guide human research, notably beneficence and non-maleficence, inherently demand that participant safety be prioritized above all other research objectives.⁷ This ethical imperative translates directly into the implementation of rigorous informed consent processes, continuous safety monitoring throughout the trial, and strict adherence to established protocols.⁷ A failure to adequately manage and report adverse events not only compromises the integrity of collected study data but can also severely erode public trust in clinical research and lead to significant regulatory penalties, including the premature termination of a trial.²

Historically, the evaluation of efficacy and toxicity in clinical trials has often exhibited an asymmetry, with drug registration processes tending to prioritize formal efficacy trials while assessing toxicity with less rigor.¹⁰ The current stringent regulatory frameworks, such as those established by the International Council for Harmonisation (ICH), the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA), are a direct response to this historical imbalance. The emphasis on comprehensive adverse event reporting, including nuanced distinctions and expedited timelines, represents a maturation of pharmacovigilance. This evolution aims to achieve a more symmetrical and holistic assessment of a medical product’s true value, encompassing both its potential benefits and its associated harms. This continuous refinement of reporting standards reflects an ongoing commitment to learn from past deficiencies and enhance the protection afforded to clinical trial participants.

2. Defining Adverse Events: A Lexicon for Clinical Research

Precise terminology is essential in clinical safety to ensure consistent understanding and accurate reporting. The following definitions form the bedrock of adverse event management.

2.1. Adverse Event (AE)

An Adverse Event (AE), sometimes referred to as an Adverse Experience, is broadly defined as any untoward medical occurrence in a patient or clinical investigation subject who has been administered a pharmaceutical product. Crucially, this definition does not necessarily imply a causal relationship with the treatment.³ An AE can therefore encompass any unfavorable and unintended sign (including an abnormal laboratory finding or physical exam finding), symptom, or disease that is temporally associated with the use of a medicinal product, regardless of whether it is ultimately considered related to the product.²

Adverse events can manifest in diverse ways, including physical events (e.g., a rash), psychological events (e.g., altered cognition), or abnormal laboratory results (e.g., elevated creatinine).⁶ They also include the exacerbation of a pre-existing medical condition.⁶ All AEs, irrespective of their perceived relatedness to the investigational product, must be meticulously recorded on the Case Report Form (CRF) and in the patient’s medical notes, unless the study protocol explicitly states otherwise.¹

2.2. Adverse Drug Reaction (ADR)

An Adverse Drug Reaction (ADR) is a subset of adverse events where a causal relationship between the medicinal product and the event is considered at least a “reasonable possibility”.¹ In the pre-approval clinical experience, all noxious and unintended responses to a medicinal product, irrespective of the dose administered, are categorized as ADRs.³ It is important to note that the older term “side effect” is discouraged in modern pharmacovigilance and should not be used interchangeably with adverse event or adverse reaction, as its varied historical usage can be misleading.³

A critical distinction exists between an Adverse Drug Reaction (ADR) and an Adverse Drug Event (ADE). An ADE is a broader term, defined as “Harm caused by appropriate or inappropriate use of a drug,” encompassing scenarios such as provider error, patient non-adherence, or incorrect dosages. ADRs, conversely, represent a specific subset of ADEs where the harm is directly caused by the drug when used appropriately (i.e., at normal doses).¹⁶ This differentiation holds significant implications for clinical decision-making and the interpretation of safety data.¹⁶

2.3. Serious Adverse Event (SAE)

A Serious Adverse Event (SAE) signifies any untoward medical occurrence that, at any dose, leads to specific severe outcomes.¹ These outcomes are:

• Death.¹
• Life-threatening, which means the patient was at immediate risk of death from the event, not merely a hypothetical possibility.¹
• Requires inpatient hospitalization or prolongation of existing hospitalization.¹
• Results in persistent or significant disability or incapacity.¹
• Results in a congenital anomaly or birth defect.¹
• Other important medical events that, while not immediately life-threatening or leading to hospitalization, may jeopardize the patient and necessitate medical or surgical intervention to prevent one of the listed outcomes.⁵ Examples include intensive emergency room treatment for severe allergic bronchospasm, blood dyscrasias, or convulsions that do not require hospitalization.⁵

SAEs typically necessitate immediate reporting to the study sponsor, often within 24 hours of the investigator’s knowledge.¹

2.4. Unexpected Adverse Drug Reaction (UADR/SUSAR)

An Unexpected Adverse Drug Reaction (UADR), frequently referred to as a Suspected Unexpected Serious Adverse Reaction (SUSAR) when serious, is an adverse reaction whose nature or severity is not consistent with the applicable product information. This includes the Investigator’s Brochure for an unapproved investigational medicinal product or the package insert for an approved product.³

This definition encompasses events not explicitly listed in the investigator’s brochure, or those listed but observed with a higher specificity or severity than previously documented.¹⁵ Reports that provide significant new information on the specificity or severity of an already documented serious ADR are also considered unexpected.⁵ The concept of “unexpectedness” functions as a dynamic indicator of evolving safety profiles. It signals that an observed adverse reaction deviates from the current understanding of the investigational product’s risks, as detailed in the Investigator’s Brochure.³ This necessitates a continuous learning process in drug development: as more data accumulates, the “expected” profile of a drug evolves. An event once considered unexpected might become expected, and conversely, a known event presenting with new characteristics (e.g., higher severity, different manifestation) can become unexpected. This dynamic nature mandates constant updating of product information and diligent comparison of new events against the most current safety knowledge. Consequently, even a seemingly minor deviation in severity for a known event can trigger expedited reporting if it signifies a new, more serious risk profile, prompting a re-evaluation of the drug’s overall risk-benefit.

2.5. Distinguishing Key Terms: Severity vs. Seriousness

A crucial distinction in AE classification exists between “severity” and “seriousness.” “Severity” describes the intensity or grade of a specific event (e.g., mild, moderate, or severe headache), indicating its impact on the patient’s daily activities.⁴ In contrast, “seriousness” is a regulatory criterion based on the patient’s outcome or the action taken (e.g., hospitalization, life-threatening nature).⁴

An event can be severe without being serious (e.g., a severe rash is typically not an SAE), and conversely, a mild event can be serious if it leads to a serious outcome (e.g., mild chest pain resulting in hospitalization is an SAE).⁴ Seriousness, not severity, is the primary determinant for defining regulatory reporting obligations.⁵

The regulatory standard of “reasonable possibility” for establishing causality in an Adverse Drug Reaction (ADR) ³ is a deliberate mechanism designed to prioritize early safety signal detection over absolute scientific certainty. In the dynamic and often uncertain environment of clinical trials, delaying action to await irrefutable proof of causation could expose trial participants to undue risks. By accepting a “reasonable possibility” as the threshold, regulatory bodies ensure that potential drug-related harms are flagged and investigated promptly, even if the evidence is not yet conclusive. This proactive approach minimizes the risk to trial participants and future patients by enabling rapid communication and potential protocol adjustments.³ This commitment to safety is further reinforced by the principle that an investigator’s causality assessment can be upgraded (from unrelated to related) but not downgraded by the sponsor ¹⁹, ensuring that potential signals are not dismissed prematurely.

Table 1: Comparative Definitions of AE, ADR, SAE, and Unexpected ADR (ICH, FDA, EMA Perspectives)

Term	ICH Definition	FDA Definition	EMA Definition	Key Characteristics/Nuances
Adverse Event (AE)	Any untoward medical occurrence in a patient or subject administered a product, not necessarily causal. Unfavorable/unintended sign, symptom, or disease temporally associated with product use. 3	Any untoward medical occurrence associated with drug use, regardless of drug-relatedness. Unfavorable/unintended sign, symptom, or disease temporally associated with drug use. 4	Any untoward medical occurrence in a patient or subject administered a product, not necessarily causal. Unfavorable/unintended sign, symptom, or disease temporally associated with product use. 5	Temporal association; causality not implied; includes abnormal lab findings, worsening pre-existing conditions.
Adverse Drug Reaction (ADR)	Noxious and unintended response to a product where causal relationship is at least a “reasonable possibility” (pre-approval). Noxious and unintended response at normal doses (post-marketing). 3	Any AE for which there is a “reasonable possibility” that the drug caused the event. 15	All noxious and unintended responses to a medicinal product related to any dose (pre-approval); “reasonable possibility” of causal relationship. 5	Causal relationship (reasonable possibility) implied; subset of AE; “side effect” term discouraged.
Serious Adverse Event (SAE)	Any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation, results in persistent/significant disability/incapacity, or is a congenital anomaly/birth defect. 5	Any AE or suspected AR that results in death, is life-threatening, requires inpatient hospitalization or prolongation, results in persistent/significant incapacity/disruption of normal life functions, or is a congenital anomaly/birth defect. Also, other important medical events. 15	Any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation, results in persistent/significant disability/incapacity, or is a congenital anomaly/birth defect. Also, other important medical events. 5	Outcome-based criterion; guides regulatory reporting; distinct from “severity.”
Unexpected Adverse Drug Reaction	An ADR whose nature or severity is not consistent with applicable product information (e.g., Investigator’s Brochure). 3	An AE or suspected AR not listed in Investigator’s Brochure or not listed at observed specificity/severity. 15	An ADR whose nature or severity is not consistent with applicable product information (e.g., Investigator’s Brochure). 5	Deviation from known risk profile; implies new safety information; can include new manifestations or increased severity of known events.

3. Classification of Adverse Events: A Framework for Assessment

The systematic classification of adverse events is paramount for their proper assessment and subsequent reporting, providing a structured framework for understanding their clinical significance.

3.1. Severity Assessment

Severity refers to the intensity or grade of an adverse event, commonly categorized as Mild, Moderate, or Severe.⁴ This classification helps gauge the immediate impact of the event on the participant’s daily life and the level of medical intervention required.

• Mild: Symptoms are generally easily tolerated, cause minor irritation, and do not significantly interfere with normal daily activities. They typically do not necessitate specific therapy or a medical evaluation.⁴
• Moderate: Events introduce a low level of inconvenience or concern, may interfere with daily activities to some extent, but are usually manageable with simple therapeutic measures.⁴
• Severe: These events significantly interrupt normal daily activities, often require systemic drug therapy or other substantial treatment, and are usually incapacitating.⁴

It is vital to reiterate that severity is distinct from seriousness.⁴ Seriousness, based on the outcome of the event (e.g., hospitalization, life-threatening nature), is the primary criterion guiding regulatory reporting obligations.⁵

3.2. Expectedness Assessment

Expectedness classifies adverse events based on whether their occurrence was anticipated given the current knowledge of the investigational product. This assessment relies heavily on information detailed in the study protocol, the Investigator’s Brochure, product insert, or label.⁴

• Unexpected: An event is deemed unexpected if its nature or severity is not consistent with the information about the condition under study or the intervention, as detailed in the protocol, informed consent form, product brochure, or investigator brochure.⁴ This includes events not explicitly listed or those listed but observed with a higher specificity or severity than previously documented.¹⁵
• Expected: An event is considered expected if it is known to be associated with the intervention or the condition under study.¹¹

3.3. Causality Assessment

Causality assessment determines the likelihood of a causal relationship between the adverse event and the investigational product. This step is critical for classifying an AE as an Adverse Drug Reaction (ADR).³ Common categories for causality include:

• Definitely Related: The event is clearly linked to the investigational agent, following a reasonable temporal sequence, matching a known or expected response pattern, and potentially confirmed by dechallenge (improvement upon stopping the drug) and rechallenge (reappearance upon re-administration).⁴
• Possibly Related: The event follows a reasonable temporal sequence and a known or expected response pattern, but other factors could also have readily produced it.⁴
• Not Related: The event is clearly not related to the investigational agent, with another cause being more plausible, an inconsistent temporal sequence, or a biologically implausible causal relationship.⁴

Causality assessment is mandatory for clinical investigation cases to qualify as ADRs for reporting purposes.³ For spontaneous reports involving marketed drugs, causality is often implied.³ While investigators provide their initial causality assessment to the sponsor ²², the sponsor makes the final determination for expedited reporting to regulatory authorities.¹⁵ Importantly, an investigator’s causality assessment can be

upgraded (e.g., from unrelated to related) but not downgraded by the sponsor ¹⁹, which reflects a cautious approach to safety. If causality cannot be definitively determined, Serious Adverse Events (SAEs) should generally be considered related and reported as Suspected Unexpected Serious Adverse Reactions (SUSARs) if they are not expected.¹⁹

The classification of an adverse event is not a series of isolated assessments but a hierarchical and interdependent process that directly dictates regulatory reporting obligations. An event’s seriousness serves as the primary filter for expedited reporting, but its expectedness and causality then refine whether it constitutes a critical new safety signal (a SUSAR) requiring urgent attention. For instance, a severe headache, despite its high severity, is typically not an SAE, whereas mild chest pain leading to hospitalization, despite its lower severity, is categorized as an SAE.⁴ Furthermore, a serious event that is

expected and not drug-related typically does not warrant expedited reporting.³ This multi-dimensional classification system ensures that regulatory bodies receive targeted information on events that represent

new or significantly altered risks of the investigational product, preventing information overload while prioritizing the most impactful safety signals.

4. The Significance of Adverse Event Reporting

Rigorous adverse event reporting is not merely a procedural requirement; it is a fundamental cornerstone of ethical research, data integrity, and informed decision-making throughout the drug development lifecycle.

4.1. Ensuring Participant Safety

The meticulous identification, comprehensive reporting, and proactive management of adverse events are paramount for ensuring the safety and well-being of clinical trial participants.² This systematic process facilitates the early detection of potential safety signals, allows for prompt assessment of their severity and causality, and enables the timely implementation of appropriate mitigating actions. Such actions may include dose adjustments, temporary discontinuation of the treatment, or even hospitalization in severe cases.² Prioritizing participant well-being is not only an ethical obligation inherent in human research but also a fundamental regulatory requirement.²

4.2. Maintaining Data Integrity and Research Credibility

Accurate and timely reporting of adverse events is crucial for maintaining the integrity of data collected in clinical research.² It ensures that the safety profile of the investigational product is truly and comprehensively reflected in the study outcomes, which is vital for the credibility of the research and the trustworthiness of its findings.² Inadequate management or reporting of AEs can skew study results, introduce bias, and potentially compromise the statistical power of the trial, leading to erroneous conclusions about a drug’s efficacy or safety.⁷ Adherence to Good Clinical Practice (GCP) standards, which explicitly include robust AE reporting, is essential for generating credible and regulatory-acceptable data.²

4.3. Informing Risk-Benefit Assessment

The data derived from adverse events is indispensable for conducting a comprehensive risk-benefit assessment of a medical intervention.² This assessment, which involves comparing the potential benefits (e.g., efficacy in treating a disease) against potential risks (e.g., occurrence of AEs), is a critical factor in the decision-making process for regulatory approval and subsequent clinical use.² Comprehensive AE data empowers researchers to refine study methodologies, adjust dosages, or modify protocols as new safety information emerges, ensuring that the development pathway remains responsive to evolving safety knowledge.⁷

4.4. Regulatory Compliance and Public Trust

Compliance with adverse event reporting regulations is a non-negotiable aspect of clinical research. Non-compliance can lead to severe consequences, including the premature termination of a trial, substantial financial penalties, and a significant loss of credibility for all involved researchers, sponsors, and institutions.² Transparency in reporting safety issues and risk management strategies is a cornerstone for building and maintaining public trust in scientific inquiry.⁷ Conversely, any lapse in patient safety or failure in transparent reporting can result in regulatory sanctions and a steep decline in public confidence in clinical research, hindering future advancements.⁷

The significance of adverse event reporting extends beyond its immediate function of regulatory compliance and patient protection; it serves as a powerful, iterative mechanism for continuous quality improvement within clinical research and drug development. Each reported AE, particularly a Suspected Unexpected Serious Adverse Reaction (SUSAR), is not merely a static data point but a dynamic signal that can trigger a re-evaluation of the investigational product’s safety profile, the study design, and patient management strategies. This feedback loop, leading to protocol amendments, updated informed consent forms, and refined clinical practices ², transforms individual adverse occurrences into collective learning opportunities. This proactive adaptation fosters a culture of vigilance and responsiveness, ultimately leading to the development of safer and more effective medical interventions and strengthening the overall scientific rigor and ethical foundation of clinical research.

5. Regulatory Frameworks and Reporting Requirements

Adverse event reporting in clinical research is governed by stringent regulatory guidelines, with a strong emphasis on harmonized international standards and specific requirements from major regulatory bodies.

5.1. International Harmonization (ICH E2A)

The International Conference on Harmonisation (ICH) E2A guideline provides globally harmonized standards for clinical safety data management, specifically focusing on expedited reporting during the investigational (pre-approval) phase.³ Its primary objectives are to establish standard definitions and terminology and to define mechanisms for rapid reporting, thereby ensuring uniform Good Clinical Practice (GCP) standards across different regions.⁵

Under ICH E2A, all Adverse Drug Reactions (ADRs) that are both serious and unexpected (i.e., SUSARs) are subject to expedited reporting.³ Expedited reporting is generally considered inappropriate for serious but expected reactions, serious events from clinical investigations not related to the study product, and non-serious adverse reactions (whether expected or not).³ A causality assessment is a prerequisite for clinical investigation cases to qualify as ADRs for reporting purposes.³

5.2. FDA Safety Reporting Requirements (21 CFR 312.32)

The U.S. Food and Drug Administration (FDA) details its safety reporting requirements for Investigational New Drug (IND) applications in 21 CFR 312.32.¹⁵ Sponsors are mandated to notify the FDA and all participating investigators of potentially serious risks identified from clinical trials or any other source as soon as possible, but no later than 15 calendar days after determining that the information qualifies for reporting.¹⁵

Criteria for Submitting an IND Safety Report: A sponsor must submit an IND safety report when any of the following criteria are met ¹⁵:

• Serious and Unexpected Suspected Adverse Reaction: The event must satisfy all three definitions: suspected adverse reaction (implying a reasonable possibility of drug causation), serious, and unexpected.¹⁵ Examples include rare events strongly associated with drug exposure (e.g., angioedema, blood dyscrasias, hepatic injury, Stevens-Johnson Syndrome) or uncommon events with a strong temporal association or recurrence upon rechallenge (e.g., tendon rupture or heart valve lesions in young adults).¹⁵ For serious events anticipated to occur independently of drug exposure (e.g., consequences of an underlying disease), reporting is required if an aggregate analysis indicates a higher frequency in the drug treatment group compared to a concurrent or historical control group.¹⁵
• Findings From Other Sources: This includes clinically important findings from other clinical or epidemiological studies (e.g., drug interaction studies, QT interval studies) or from animal or in vitro testing that suggest a significant risk in humans (e.g., carcinogenicity, mutagenicity, teratogenicity, or significant organ toxicity at or near expected human exposure).¹⁵
• Increased Occurrence of Serious Suspected Adverse Reactions: This criterion applies to a clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure.¹⁵

Reporting Timelines (FDA):

• Unexpected Fatal or Life-Threatening Suspected Adverse Reactions: Notification to regulatory agencies must occur as soon as possible, but no later than 7 calendar days after the sponsor’s initial receipt of the information. A complete report must follow within an additional 8 calendar days, including an assessment of the findings’ importance and implications.¹⁵
• All Other Serious, Unexpected Suspected Adverse Reactions: These must be filed as soon as possible, but no later than 15 calendar days after the sponsor’s first knowledge that the case meets the minimum criteria for reporting.¹⁵
• Follow-up Information: Any relevant additional information pertaining to a previously submitted IND safety report must be submitted as a Follow-up IND Safety Report without delay, as soon as it becomes available, but no later than 15 calendar days after receipt.¹⁵

Format and Unblinding: Sponsors typically utilize FDA Form 3500A or the CIOMS I Form for individual reports.¹⁵ For expedited reports submitted to the FDA and investigators, the blind should ordinarily be broken for the specific patient involved, as knowledge of the treatment assignment is necessary for proper interpretation and subject management.⁵

5.3. EMA Expedited Reporting Procedures

The European Medicines Agency (EMA) adheres to the ICH E2A guideline for expedited reporting, underscoring the importance of harmonized standards for clinical safety data management.⁵

What to Report: Similar to ICH and FDA requirements, the EMA mandates expedited reporting for single cases of serious, unexpected ADRs (SUSARs) from any source, including spontaneous reports, clinical investigations, or publications.⁵ Rapid communication may also be necessary for other observations that materially influence the benefit-risk assessment or would lead to changes in product administration or clinical investigation conduct. Examples include a clinically important increase in the rate of an “expected” serious ADR, a significant hazard to the patient population such as lack of efficacy for a life-threatening disease, or major safety findings from a newly completed animal study (e.g., carcinogenicity).⁵

Reporting Time Frames (EMA): These align with ICH E2A and FDA requirements: 7 calendar days for initial fatal or life-threatening SUSARs (with a complete report within an additional 8 days), and 15 calendar days for all other serious, unexpected ADRs.⁵

Minimum Criteria for Reporting: An initial report must include an identifiable patient, a suspect medicinal product, an identifiable reporting source, and an event or outcome identified as serious and unexpected, with a reasonable suspected causal relationship in clinical investigation cases.⁵

How to Report: The CIOMS-I form is a widely accepted standard for reporting to regulatory authorities.⁵

5.4. Reporting Study Endpoints vs. Adverse Events

A key distinction in reporting involves study endpoints, which are outcomes measured for efficacy. These are generally reported according to the study protocol and are not typically considered IND safety reports for expedited submission (e.g., all-cause mortality in an oncology trial).¹⁵ However, if there is evidence suggesting a causal relationship between the investigational drug and a serious study endpoint (e.g., death from anaphylaxis), then it

must be reported expeditiously as an IND safety report.¹⁵ Serious adverse events that are not study endpoints but are anticipated to occur with some frequency should be monitored and reported expeditiously if aggregate analysis reveals an imbalance suggesting drug causation.¹⁵

The underlying principle driving expedited safety reporting is the rapid dissemination of new, critical safety information that could fundamentally alter the known risk-benefit profile of an investigational product or necessitate immediate changes in its development, administration, or patient monitoring. Regulatory bodies are not seeking individual reports of every serious event if it represents an already known and anticipated risk (e.g., expected myelosuppression with a chemotherapy agent).³ Rather, they are specifically interested in signals that reveal previously unknown risks, a significant increase in the frequency or severity of known risks, or a causal link to the drug for events previously considered unrelated. This targeted approach prevents information overload for regulators while ensuring that genuinely novel and impactful safety concerns are acted upon swiftly, thereby protecting current and future patients from unforeseen harms.

Table 2: Expedited Reporting Timelines and Criteria (Fatal/Life-Threatening vs. Other Serious Unexpected ADRs)

Type of Event	Reporting Timeline (Sponsor’s First Knowledge)	Regulatory Basis	Key Conditions
Fatal or Life-Threatening Unexpected Suspected Adverse Reaction	As soon as possible, but no later than 7 calendar days. Complete report within an additional 8 calendar days. 5	ICH E2A, FDA (21 CFR 312.32), EMA	Requires identifiable patient, suspect product, reporting source, serious & unexpected event, and reasonable suspected causal relationship (for clinical investigations). Blind ordinarily broken for patient.
All Other Serious, Unexpected Suspected Adverse Reactions	As soon as possible, but no later than 15 calendar days. 5	ICH E2A, FDA (21 CFR 312.32), EMA	Requires identifiable patient, suspect product, reporting source, serious & unexpected event, and reasonable suspected causal relationship (for clinical investigations). Blind ordinarily broken for patient.

6. Roles and Responsibilities in AE Reporting

The effective management of adverse events in clinical research relies on the distinct yet interconnected roles and responsibilities of key stakeholders.

6.1. Investigator Responsibilities

The investigator, typically the Principal Investigator (PI), holds the primary responsibility for the medical care and safety of the trial participant throughout the study.⁸ This encompasses the assessment and management of any adverse events that occur.

Investigators are mandated to immediately report all Serious Adverse Events (SAEs) to the study sponsor, irrespective of whether they are considered drug-related, typically within 24 hours of becoming aware of the event.¹ The protocol may specify exceptions for certain expected SAEs.¹⁹ In their reports to the sponsor, investigators must include an assessment of whether there is a “reasonable possibility” that the investigational drug caused the event.¹¹ While the investigator provides this initial assessment, the sponsor makes the final determination for expedited reporting to regulatory authorities.¹⁵ It is important to note that an investigator’s causality assessment can be upgraded by the sponsor (e.g., from unrelated to related) but not downgraded ¹⁹, emphasizing a cautious approach to safety.

Following the immediate notification, investigators are responsible for submitting a detailed written SAE report, typically within 14 calendar days.¹ They must accurately record and document all adverse events (both serious and non-serious) in source documents (e.g., medical notes) and Case Report Forms (CRFs) or adverse event logs.¹ Maintaining adequate and accurate case histories is essential.²² Non-serious AEs are reported to the sponsor according to the protocol’s specified timetable, and causality assessment is generally not required for these by regulations.¹⁵

Investigators must also promptly report “unanticipated problems involving risks to human subjects or others” to their local Institutional Review Board (IRB).¹¹ This category includes adverse events that are unexpected, serious, and related or possibly related to study participation.⁴

6.2. Sponsor Responsibilities

The sponsor bears the ultimate responsibility for the ongoing safety evaluation of the investigational product.⁸ This involves systematically reviewing all safety information from diverse sources, including data from multiple clinical sites, other human studies, animal studies, in vitro testing, and published scientific literature.¹⁵

Sponsors must conduct periodic reviews and aggregate analyses of their entire safety database to identify new safety signals, update the known safety profile, and ensure the Investigator Brochure, protocols, and consent forms reflect current safety information.¹⁵ They are responsible for submitting IND safety reports (to the FDA) or expedited reports (to the EMA) for all serious, unexpected suspected adverse reactions (SUSARs), and other significant safety findings.⁵ Strict adherence to reporting timelines (7-day for fatal/life-threatening, 15-day for other serious unexpected) is mandatory.⁵

Sponsors must keep all participating investigators informed of new safety observations, particularly concerning adverse effects and safe use.²² This is typically achieved through updated Investigator Brochures or “investigator letters” that summarize new safety information and updated benefit-risk evaluations.⁵ In blinded studies, sponsors are generally advised to break the blind for specific patients experiencing reportable serious events, even if the investigator has not, to facilitate proper reporting and patient management. However, the blind should be maintained for personnel involved in the overall analysis to preserve study integrity.⁵ Sponsors also ensure the investigation adheres to the general investigational plan and protocols ²² and are responsible for compensating participants in the event of an SAE.⁸

6.3. Ethics Committee/Institutional Review Board (IRB) Responsibilities

IRBs (also known as Ethics Committees or ECs) are independent committees tasked with protecting the rights and welfare of human subjects in research.⁹ They rigorously review research protocols and related materials (e.g., informed consent documents) for ethical compliance, legal adherence, and scientific validity before study initiation.⁹ Their role is to ensure risks are minimized and balanced against anticipated benefits.²⁴

Beyond initial approval, IRBs maintain continuous oversight throughout the study’s lifecycle. This includes reviewing protocol amendments, assessing participant enrollment and withdrawal criteria, and monitoring ongoing compliance with ethical guidelines and regulatory requirements.⁹ IRBs play a critical role in reviewing “unanticipated problems involving risks to human subjects or others”.¹⁵ An adverse event is considered an unanticipated problem if it is unexpected, serious, and related or possibly related to study participation.⁴ The IRB reviews proposed corrective actions for appropriateness and is responsible for reporting these unanticipated problems to institutional officials and regulatory agencies.¹² Ultimately, IRBs are mandated to uphold core ethical principles such as beneficence, justice, non-maleficence, autonomy, confidentiality, and honesty throughout the research process.⁸

The system of adverse event reporting in clinical research functions as a highly interdependent ecosystem, rather than a collection of isolated responsibilities. The prompt and accurate reporting by investigators serves as the initial trigger for the entire safety surveillance chain.¹⁹ The sponsor then acts as the central hub, aggregating data from multiple sites and sources, conducting sophisticated analyses, and disseminating critical safety information to both regulatory authorities and other investigators.¹⁵ The IRB provides independent ethical oversight, ensuring participant protection and reviewing any unanticipated risks.⁹ A breakdown in communication or a failure in one party’s responsibility can compromise the entire system, leading to delayed signal detection, inadequate patient protection, and regulatory non-compliance. This highlights that effective AE management requires not just individual adherence to duties but a collaborative, well-coordinated effort driven by a shared commitment to patient safety and research integrity.

Table 3: Key Responsibilities of Investigators, Sponsors, and IRBs/ECs in AE Reporting

Stakeholder	Primary Responsibilities (related to AE reporting)	Key Reporting Flows
Investigator	– Medical management and patient care 8	– Immediate reporting of all SAEs to sponsor (within 24h) 1	– Causality assessment for ADRs 19	– Detailed reporting and record-keeping for all AEs 1	– Reporting “unanticipated problems involving risks” to IRB 11	– Investigator to Sponsor (all SAEs, non-serious AEs per protocol) 19	– Investigator to IRB (unanticipated problems) 11
Sponsor	– Overall safety evaluation and monitoring of investigational product 8	– Aggregate analysis and signal detection from all sources 15	– Expedited reporting of SUSARs and significant safety findings to regulatory authorities (7/15 days) 5	– Informing all investigators of new safety observations 19	– Unblinding management for reportable events 5	– Ensuring compliance with protocols and compensation for SAEs 8	– Sponsor to Regulatory Authorities (expedited reports, annual reports) 5	– Sponsor to Investigators (updated Investigator Brochures, safety letters) 19	– Sponsor to IRB (unanticipated problems, if sponsor-investigator) 23
Ethics Committee/IRB	– Ethical review and approval of research protocols 9	– Ongoing oversight throughout study lifecycle 9	– Review of “unanticipated problems involving risks” and proposed corrective actions 12	– Upholding ethical principles and participant welfare 8	– IRB to Institutional Officials/Regulatory Agencies (unanticipated problems) 12

7. Challenges and Best Practices in AE Management and Reporting

Despite the robust regulatory frameworks, the identification, assessment, and reporting of adverse events present inherent complexities and challenges that necessitate continuous refinement of practices.

7.1. Common Challenges

A significant challenge in AE ascertainment and reporting is the historical absence of universal, standardized instruments.¹⁰ This often leads to inconsistencies in how AEs are obtained, a lack of adequate information regarding timeframes, and deficiencies in severity rating and causality judgment.¹⁰ Many assessments have relied on open-ended questions or non-validated measures instead of structured symptom lists, potentially resulting in underreporting or less reliable data.²⁵

The assessment of causality can be highly subjective.¹⁰ There is a risk of misattributing symptoms that are part of the underlying illness or common minor bodily complaints to the investigational medication, thereby introducing bias into the results.²⁵ Patient expectations can also inadvertently influence reported side effects.²⁵ Unlike efficacy assessments, which often concentrate on a relatively narrow therapeutic goal, safety is inherently multi-organ and more complex. It requires careful consideration of patient-centered aspects such as the intensity, frequency, duration, and overall impact of events on daily activities.¹⁰ Historically, drug registration has placed a more rigorous focus on efficacy compared to toxicity assessment, contributing to less formal approaches to safety evaluation.¹⁰ Furthermore, failures in standardizing procedures and equipment, implementing robust safety checks, and coordinating communication between research staff and clinical care providers can lead to medication-related AEs and deficiencies in reporting.¹²

7.2. Best Practices

To overcome these challenges and enhance overall safety surveillance, several best practices are critical. Implementing standardized data collection methods and validated instruments, including patient self-report checklists and investigator-reported AE instruments, is essential to ensure consistency and reliability in data capture.¹⁰ This approach facilitates the generation of quantitative data necessary for robust risk-benefit evaluations.¹⁰

Establishing comprehensive adverse event monitoring systems that continuously review, evaluate, and manage accumulating safety data from the entire clinical trial database is paramount.⁷ This includes proactive measures to identify and prevent avoidable harm and anticipate potential problems before they escalate.¹² Developing clear communication and coordination strategies among all stakeholders is vital.¹² Sponsors should promptly notify investigators of significant safety profile changes through updated Investigator Brochures or concise investigator letters that summarize new safety information and updated benefit-risk evaluations.¹⁹

Ensuring that all research personnel involved in AE identification, assessment, and reporting receive continuous, high-quality training is fundamental. This includes instruction on using standardized forms, understanding causality assessment, and adhering to reporting timelines.¹² Implementing corrective action and quality improvement plans to minimize the likelihood of AE reoccurrence is also a critical practice.¹² This involves a thorough understanding of the trial’s risks and having established procedures to manage them effectively.¹²

Maintaining transparency in reporting safety issues and risk management strategies is crucial for building and maintaining public trust. Detailed, real-time safety updates and publicly accessible trial results contribute to an environment of trust between researchers and the public.⁷ Utilizing placebo control groups and conducting thorough baseline assessments are valuable methods to help differentiate drug-induced AEs from symptoms of the underlying disease or common bodily complaints, thereby reducing misattribution bias.²⁵ Finally, practical safety reporting tips include: when in doubt, clarify and report ¹²; if an event is reportable with available information, report immediately without waiting for additional confirmation ¹²; and in cases of a cascade of events, report the causal event rather than each individual symptom.¹²

While methodological advancements, such as standardized instruments, are crucial, a significant portion of the challenges in adverse event reporting stems from the human element—specifically, inconsistencies in training, subjective interpretations, and communication breakdowns among research personnel. This indicates that technological and procedural solutions alone are insufficient. A critical best practice must involve a sustained investment in comprehensive, ongoing training for all individuals involved in AE identification and assessment. Such training fosters a culture of vigilance, critical thinking, and open communication. The principle of “if in doubt, report!” ¹² directly addresses the human tendency to hesitate or filter information, promoting a proactive, safety-first mindset. This cultural shift, underpinned by robust training and clear, actionable protocols, is essential to overcome the inherent subjectivity and complexity of AE assessment and ensure the capture of truly comprehensive safety data.

8. Conclusion: Advancing Safety in Clinical Research

A comprehensive understanding and diligent reporting of adverse events are not merely administrative tasks but represent a fundamental scientific and ethical imperative in clinical research. Robust pharmacovigilance is the bedrock upon which the safe and effective advancement of medical knowledge is built, ensuring that new therapies are introduced with a thorough and transparent understanding of their risk-benefit profiles.

The landscape of pharmacovigilance is continuously evolving, driven by the complexities of novel therapeutic modalities and the increasing integration of real-world evidence. This necessitates an ongoing commitment to several key areas:

• Further development and widespread adoption of standardized methodologies and instruments for adverse event identification and assessment.
• Leveraging advanced data analytics and informatics to detect subtle safety signals from increasingly complex and voluminous datasets.¹²
• Strengthening collaborative efforts and communication channels among investigators, sponsors, regulatory authorities, and ethics committees to cultivate a truly unified and responsive safety ecosystem.

Ultimately, continuous vigilance, adaptability to emerging challenges, and a shared global commitment to patient protection are essential for fostering public trust and ensuring the responsible progress of clinical research, leading to safer and more effective treatments for all.

Works cited

1. Adverse event identification and reporting – International Society of Nephrology, accessed August 10, 2025, https://www.theisn.org/in-action/research/clinical-trials-isn-act/isn-act-toolkit/study-stage-iii-conducting-a-trial/adverse-event-identification-and-reporting/
2. Adverse Event – Clinical Research Explained – VIARES, accessed August 10, 2025, https://viares.com/blog/clinical-research-explained/adverse-event/
3. ICH Harmonised Tripartite Guideline Clinical Safety Data …, accessed August 10, 2025, https://database.ich.org/sites/default/files/E2A_Guideline.pdf
4. nia_ae_and_sae_guidelines.docx – National Institute on Aging, accessed August 10, 2025, https://www.nia.nih.gov/sites/default/files/2017-06/nia_ae_and_sae_guidelines.docx
5. E 2 A Clinical Safety Data Management: Definitions and … – EMA, accessed August 10, 2025, https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-topic-e-2-clinical-safety-data-management-definitions-and-standards-expedited-reporting-step_en.pdf
6. Serious Adverse Events & Safety Reporting 101 | Research In Action | Advancing Health, accessed August 10, 2025, https://www.advancinghealth.ubc.ca/research-in-action/serious-adverse-events-safety-reporting-101/
7. Patient Safety in Clinical Trials: A CRWF Guide (2025), accessed August 10, 2025, https://www.crwf.com/blog/why-patient-safety-matters-in-clinical-trials/
8. Ethics of Safety Reporting of a Clinical Trial – PMC – PubMed Central, accessed August 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5527719/
9. The Role of Ethics Committees in Clinical Trials: Ensuring Patient Safety, accessed August 10, 2025, https://tfscro.com/resources/the-role-of-ethics-committees-in-clinical-trials-ensuring-patient-safety/
10. Challenges and Progress in Adverse Event Ascertainment and Reporting in Clinical Trials | OMERACT, accessed August 10, 2025, https://omeract.org/wp-content/uploads/2023/11/3-Challenges-and-Progress-in-Adverse-Event-Ascertainment-and-Reporting-in-Clinical-Trials.pdf
11. NIA Adverse Event and Serious Adverse Event Guidelines – National Institute on Aging, accessed August 10, 2025, https://www.nia.nih.gov/sites/default/files/2018-09/nia-ae-and-sae-guidelines-2018.pdf
12. Key Concepts for Capturing and Reporting Adverse Events – USF Health, accessed August 10, 2025, https://health.usf.edu/-/media/Files/Medicine/Research/OCR/
    May21CapturingandReportingAdverseEventsMay21.ashx
13. Clinical Trials Glossary of Terms | St. Luke’s, accessed August 10, 2025, https://www.slhn.org/research/clinical-trials/glossary-of-terms
14. Classification of Adverse Events | North Bristol NHS Trust, accessed August 10, 2025, https://www.nbt.nhs.uk/research-innovation/researcher-zone/researcher-journey/study-management/safety-reporting/classification-adverse-events
15. Safety Reporting Requirements for INDs and BA/BE Studies | FDA, accessed August 10, 2025, https://www.fda.gov/files/drugs/published/Safety-Reporting-Requirements-for-INDs-%28Investigational-New-Drug-Applications%29-and-BA-BE-%28Bioavailability-Bioequivalence%29-Studies.pdf
16. Adverse Drug Events vs Adverse Drug Reaction Display of ADE information in a Patient’s PharmaNet Profile Look for the *ADE in – Gov.bc.ca, accessed August 10, 2025, https://www2.gov.bc.ca/assets/gov/health/health-drug-coverage/pharmacare/adverse_drug_events_in_pharmanet_general_cheat_sheet.pdf
17. Serious adverse event – Toolkit, accessed August 10, 2025, https://toolkit.ncats.nih.gov/glossary/serious-adverse-event/
18. Adverse Events in Clinical Trials: Definitions and Documentation, accessed August 10, 2025, https://hub.ucsf.edu/sites/g/files/tkssra261/f/6.%20Adverse%20Eventsd%20Definitions.pdf
19. (Serious) adverse events and SUSARs | Investigators – CCMO, accessed August 10, 2025, https://english.ccmo.nl/investigators/clinical-trials-with-medicinal-products-ctr/conduct-of-study-ctr/safety-reporting/serious-adverse-events-and-susars
20. www.ncbi.nlm.nih.gov, accessed August 10, 2025,
    https://www.ncbi.nlm.nih.gov/books/NBK362736/
21. Unexpected adverse event – SOM Clinical Research Glossary, accessed August 10, 2025, https://glossary.clinicalresearch.unc.edu/clinical-research-glossary/unexpected-adverse-event-or-suspected-adverse-reaction-fdas-definition-for-ind-safety-reporting/
22. 21 CFR Part 312 Subpart D — Responsibilities of Sponsors and Investigators – eCFR, accessed August 10, 2025, https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-D
23. Sponsor/Sponsor-Investigator Drug Safety Reporting Responsibilities AND Changes to Policy on Investigator Safety Information Rep, accessed August 10, 2025, https://rcra.emory.edu/_includes/documents/sections/oric/sponsor-sponsor-investigator-drug-safety-reporting-july-2012.pdf
24. Understanding Institutional Review Boards (IRBs): Roles & Responsibilities – CCRPS, accessed August 10, 2025, https://ccrps.org/clinical-research-blog/understanding-institutional-review-boards-irbs-roles-amp-responsibilities
25. Assessment of Adverse Events in Clinical Drug Trials: Identifying Amitriptyline’s Placebo- and Baseline-Controlled Side Effect – APA Divisions, accessed August 10, 2025, https://www.apadivisions.org/division-55/councils/research/adverse-effects-trials.pdf